Table 3.
IP3 cohort stratified by number of newly initiated drugs with a potential drug-gene interaction within follow-up.
| Overall IP3 Study Cohort (n = 200) |
0 (n = 6, 3%) |
1 (n = 27, 13.5%) |
2 (n = 52, 26%) |
3 (n = 50, 25%) |
≥4 (n = 65, 32.5%) |
p-Value * | |
|---|---|---|---|---|---|---|---|
| Gender | 0.775 | ||||||
| Female, n (%) | 103 (51.5) | 4 (66.7) | 12 (44.4) | 24 (46.2) | 27 (54.0) | 36 (55.4) | |
| Male, n (%) | 97 (48.5) | 2 (33.3) | 15 (55.6) | 28 (53.8) | 23 (46.0) | 29 (44.6) | |
| Age in years, Mean (SD) | 61.6 (11.2) | 53.3 (16.3) | 59.4 (10.6) | 61.0 (11.5) | 63.0 (10.5) | 62.8 (11.1) | 0.442 |
| BMI (kg/m 2 ), Mean (SD) | 28.3 (14.9) | 25.6 (2.6) | 29.1 (5.8) | 27.4 (4.5) | 27.6 (4.8) | 29.6 (25.2) | 0.854 |
| Number of comorbidities at baseline, Mean (SD) ** | 4.6 (2.5) | 3.4 (1.1) | 4.0 (2.2) | 4.0 (2.5) | 4.6 (2.3) | 5.4 (2.6) | 0.232 |
| Number of comedications at baseline, Mean (SD) ** | 4.0 (3.3) | 3.0 (2.1) | 3.4 (3.4) | 3.3 (3.4) | 3.8 (2.7) | 5.1 (3.4) | 0.279 |
SD: standard deviation; BMI: body mass index; * Univariate negative binomial regression; ** Based on n = 177 for whom data collection from GP records was completed.